Related Experiment Video
Updated: Dec 14, 2025

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease's patients
Gamze Guven1, Basar Bilgic2, Bedia Samanci2
1Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. gguven@istanbul.edu.tr.
Abstract:
'Triggering receptor expressed on myeloid cells 2' (TREM2) gene is involved in Alzheimer's disease (AD) and TREM2 mRNA expression is known to be increased in the peripheral blood cells of AD patients. In this study, we examined the expression levels of TREM2 mRNA in peripheral leukocytes of early and late-onset AD patients. We have also investigated the effect of the presence of APOE ε4 allele on TREM2 expression. TREM2 mRNA expression was analyzed in 30 early-onset AD (EOAD) patients, 38 late-onset AD (LOAD) patients, and in their age-matched controls by using quantitative real-time polymerase chain reaction. TREM2 levels in LOAD patients were higher than EOAD. Also, in elderly controls significantly higher TREM2 levels were found compared with young controls. Moreover, APOE ε4 carriers in LOAD patients exhibited significantly higher TREM2 expression levels than APOE ε4 non-carriers and elderly controls. Also, correlation analysis showed that TREM2 mRNA expression was increased by age. The differential expression of TREM2 mRNA levels between EOAD and LOAD patients might be independent of the AD disease status and results from an age-related increase in TREM2 expression. In LOAD patients, increased age and the presence of APOE ε4 allele further increase TREM2 expression. Taken together, we can suggest that age is a factor that increases TREM2 expression, and TREM2 and APOE ε4 may interact together in the pathogenesis of LOAD.
Insights
Triggering receptor expressed on myeloid cells 2 (TREM2) mRNA levels are higher in late-onset Alzheimer
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Triggering receptor expressed on myeloid cells 2 (TREM2) is implicated in Alzheimer's disease (AD).
- TREM2 mRNA expression elevates in the peripheral blood of AD patients.
- Investigating TREM2 in different AD onset types and its relation to APOE ε4 is crucial.
Purpose of the Study:
- To compare TREM2 mRNA expression in early-onset AD (EOAD) versus late-onset AD (LOAD) patients.
- To determine the influence of the APOE ε4 allele on TREM2 expression in AD.
- To explore the relationship between age and TREM2 expression in AD.
Main Methods:
- Quantitative real-time polymerase chain reaction (qPCR) was used.
- TREM2 mRNA levels were analyzed in 30 EOAD patients, 38 LOAD patients, and age-matched controls.
- APOE ε4 carrier status was assessed.
Main Results:
- TREM2 mRNA levels were significantly higher in LOAD patients compared to EOAD patients.
- Elderly controls showed higher TREM2 levels than young controls.
- APOE ε4 carriers with LOAD exhibited elevated TREM2 expression compared to non-carriers and elderly controls.
- TREM2 mRNA expression correlated positively with age.
Conclusions:
- Age-related increases in TREM2 expression may contribute to differential expression between EOAD and LOAD.
- In LOAD, advanced age and APOE ε4 allele presence synergistically elevate TREM2 expression.
- TREM2 and APOE ε4 may interact in the pathogenesis of LOAD.
More Related Videos
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment